• Giuseppe TridenteEmail author


Rilonacept (Arcalyst®, Regeneron) is a dimeric fusion protein combining the extracellular portion of human interleukin Type I receptor (IL.1RI) and the IL-1 receptor accessory protein (IL-1RAcP) with the Fc portion of human IgG1. Acting as a decoy receptor for both IL-1α and IL-1β, rilonacept inhibits their interaction with the natural receptors and therefore the expression of the consequent bioactivity of the bound cytokines.


Familial Mediterranean Fever Orphan Drug Actinic Keratosis Injection Site Reaction Familial Mediterranean Fever Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rilonacept (Arcalyst®) BLA 125249 Medical Review FDA, Dec 2008Google Scholar
  2. 2.
    Rilonacept (Arcalyst®) Prescribing Information Regeneron Apr 2009Google Scholar
  3. 3.
    Rilonacept (Arcalyst®) WX500026509 CHMP Assessment Report EMEA, July 2009Google Scholar
  4. 4.
    Rilonacept (Arcalyst®) ADAC Briefing materials Regeneron, May 2012Google Scholar
  5. 5.
    Boraschi D, Bossù P, Macchia G et al (1995) Structure-function relationship in the IL-1 family. Frontiers Biosci 1:270–308Google Scholar
  6. 6.
    Dubois EA, Rissmann R, Cohen AF (2011) Rilonacept and canakinumab. BJCP 71:639–641Google Scholar
  7. 7.
    Hoffman HM, Throne ML, Amar NJ et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopirin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34:2091–2103PubMedCrossRefGoogle Scholar
  8. 8.
    Schumacher HR, Evans RR, Saag KG et al (2012) Rilonacept (interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthr Care Res 64:1462–1470CrossRefGoogle Scholar
  9. 9.
    Terkeltaub RA, Schumacher HR, Carter JD et al (2013) Rilonacept in the treatment of acute arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthr Res Ther 15:R25. doi: 10.1186/ar4159 CrossRefGoogle Scholar
  10. 10.
    Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Rev Drug Discovery 11:633–652CrossRefGoogle Scholar
  11. 11.
    Hashkes PJ, Spalding SJ, Giannini EH et al (2012) Rilonacept for colchicine-resistant or –intolerant Familial Mediterranean Fever. Ann Int Med 157:533–541PubMedCrossRefGoogle Scholar
  12. 12.
    Petrynia O, Cush JJ, Efthimiou P (2012) IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis 71:2056–2058CrossRefGoogle Scholar
  13. 13.
    Henderson Cailin (1831) Wilson et al. (2010) Safety and efficacy of IL-1 Trap in resistant adult onset Still’s disease: 24 month follow-up of open label treatment and biomarkers of response (abstract). Arthritis Rheum 62:s10. doi: 10.1002/art.29596 Google Scholar
  14. 14.
    Krause K, Weller K, Stefaniak R et al (2012) Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67:943–950PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations